Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Bioactive lipid" patented technology

The sphingolipids constitute an important class of bioactive lipids, including ceramide and sphingosine-1-phosphate (S1P). Ceramide can be considered to function as a hub in sphingolipid metabolism, and it mediates or regulates antiproliferative responses such as growth inhibition, apoptosis, differentiation and senescence,...

Determination of biological characteristics of embryos fertilized in vitro by assaying for bioactive lipids in culture media

The present invention provides methods for determining various biological characteristics of in vitro fertilized embryos, including overall embryo health, implantability, and increased likelihood of developing successfully to term. More specifically, the present invention concerns analyzing media specimens of in vitro fertilization cultures for levels of bioactive lipids in order to determine these characteristics.
Owner:LPL TECH

Novel Bioactive Lipid Derivatives, and Methods of Making and Using Same

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.
Owner:APOLLO ENDOSURGERY INC

Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions

The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and / or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
Owner:LPATH

Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye

The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and / or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
Owner:LPATH

Glycoproteins having lipid mobilizing properties and therapeutic applications thereof

A biologically active lipid mobilizing agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.
Owner:ASTON UNIV

Clearance of bioactive lipids from membrane structures by cyclodextrins

The present invention provides a method of treating a subject suffering from wet acute macular degeneration which comprises administering to the subject an amount of a modified alpha cyclodextrin effective to treat the subject, wherein the modified alpha cyclodextrin binds to bioactive lipids which accumulate in the subject's eye and are characterized by the presence of a single chain of fatty acids.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Methods for decreasing immune response and treating immune conditions

The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
Owner:APOLLO ENDOSURGERY INC

Immune-Derived Moieties Reactive Against Lysophosphatidic Acid

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.
Owner:APOLLO ENDOSURGERY INC

Determining existence of complications in pregnancies by measuring levels of bioactive lipids

The present invention relates generally to methods for detecting complications, or abnormal conditions occurring during pregnancy, including placental abnormalities, eclampsia, or preelcampsia. The present invention comprises the steps of obtaining a sample from a patient, assaying the specimen to determine the level of bioactive lipids and comparing levels in the sample to control values or levels in normal samples, and correlating alterations to disease. The invention includes measuring panels of bioactive lipids to screen patients for disease and to monitor the progress of disease for diagnostic or therapeutic purposes.
Owner:LPL TECH

Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer

The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is at least 1.5 and optionally a lipid matrix composed of liposome forming lipids. Specific lipid assemblies according to the invention comprise the biologically active lipid, ceramide, a lipid derivatized with polyethylene glycol (lipopolymer) and optionally in combination with a phospholipid (e.g. Egg phosphatidylcholine (EPC) and hydrogenated soybean phosphatidylcholine (HSPC)). The lipid assemblies of the invention exhibited a therapeutic effect in vitro in tumor cells as well as in vivo in animal models and they deliver the biologically active lipid to the disease site.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD

Methods and Reagents for Detecting Bioactive Lipids

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.
Owner:APOLLO ENDOSURGERY INC

Compositions and methods for treating ocular diseases and conditions

The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and / or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1 -phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.
Owner:LPATH INC (US)

Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.
Owner:SABBADINI ROGER A +2

Human lung surfactant protein, sp-d, modulates eosinophil activation and survival and enhances phagocytosis of apoptotic bosinophils

The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
Owner:COUNCIL OF SCI & IND RES

Human lung surfactant protein, SP-D, modulates eosinophil activation and survival and enhances phagocytosis of apoptotic bosinophils

The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
Owner:COUNCIL OF SCI & IND RES

Bionic lovastatin nano-structured lipid carrier and preparation method thereof

The invention relates to the field of pharmaceutical preparation, and in particular relates to a bionic lovastatin nano-structured lipid carrier and a preparation method thereof. The method is characterized in that endogenic lipid material is adopted so as to encapsulate medicines in the carrier, so that injection for intravenous injection can be produced. The prepared nano-structured lipid carrier has good biocompatibility and is biodegradable, and toxic and side effects are reduced; the bionic lovastatin nano-structured lipid carrier has small grain size, high dispersity, good stability and can long-lastingly and slowly release medicines; and lovastatin medicines and the bioactive lipid carrier can be combined together so as to achieve a collaborative treatment function, and the curative effect of the medicine in treating cardiovascular disease is increased.
Owner:CHINA PHARM UNIV

Composition of bioactive lipids and methods of use thereof

The present application is generally directed to compositions comprising a bioactive lipid, a stabilizing agent, a solution, and ethanol. Methods associated with the preparation and use of such compositions, for example, for treating, preventing, or reversing diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity in children, or diabetic macular edema in a subject in need thereof, are also provided.
Owner:UND LIFE SCI LLC

Method of preparing bioactive phospholipid from tuna eyes

The invention discloses a method of preparing bioactive phospholipid from tuna eyes. The method includes: subjecting tuna eyes as a raw material to low temperature homogenization, extracting lipid oftuna eyes at room temperature by means of ultrasonic-assisted ethanol extraction, carrying out low-temperature low-pressure distillation to obtain a lipid component, subjecting the lipid to chromatography on silica gel columns, eluting with dichloromethane, acetone and methanol successively, collecting methanol eluate, and carrying out molecular distillation to obtain tuna eye active phospholipid.The method helps promote the benign development of the tuna processing industry and enrich the markets of marine bioactive lipids, and is positively significant to the human health and the development of marine health food industry.
Owner:ZHEJIANG OCEAN UNIV

Compositions and methods for treating ocular diseases and conditions

The present invention relates to compositions and methods for the prevention and treatment of diseases and conditions, especially eye diseases or diseases, characterized by abnormal fibrosis or scarring, inflammation and / or abnormal neovascularization or angiogenesis . The compositions and methods of the invention utilize immunogenic moieties that are specifically reactive with bioactive lipid sphingosine-1-phosphate and variants thereof, which moieties are capable of reducing the effective concentration of the targeted bioactive lipid. In one embodiment, the immunogenic moiety is a humanized monoclonal antibody reactive with sphingosine-1-phosphate.
Owner:LPATH INC (US)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products